“Combination therapy with (Opdivo) plus (Yervoy) warrants further studies in the preoperative setting for patients with resectable hepatocellular carcinoma, which could transform the role of ...

Historically, there has been limited evidence to suggest the appropriate treatment sequencing of this melanoma patient population. However, new findings demonstrate starting with Opdivo plus Yervoy ...

Positive results mark the first time an immune checkpoint inhibitor-based combination has demonstrated superior efficacy versus chemotherapy as neoadjuvant therapy in a Phase 3 trial in resectable non ...

Study evaluated Opdivo plus low-dose Yervoy given concomitantly with two cycles of chemotherapy vs. chemotherapy alone for the first-line treatment of advanced non-small cell lung cancer PRINCETON, ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the ...

The approval was based on data from the phase 3 CheckMate-274 trial which evaluated nivolumab as an adjuvant treatment in 699 adults who have undergone radical surgery for invasive urothelial ...

The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...

Opdivo is a programmed death receptor-1 blocking antibody. (Credit: Getty Images.) The Food and Drug Administration (FDA) has approved Opdivo® (nivolumab) for the adjuvant treatment of completely ...

Opdivo (nivolumab) is a prescription drug approved to treat non-small cell lung cancer (NSCLC). Opdivo is available only as a brand-name medication. It’s not available in a generic version. Opdivo ...

The approval was based on data from the phase 3 CheckMate-274 trial which evaluated nivolumab as an adjuvant treatment in 699 adults who have undergone radical surgery for invasive urothelial ...